相关实验视频
Updated: Jan 11, 2026

Assessment of the Metabolic Profile of Primary Leukemia Cells
Published on: November 21, 2018
瘤微环境中的新陈代谢:对病原和治疗学的影响
Jonas Aakre Wik1,2, Emma Riiser Berge3, Kristine Stromsnes3
1Hybrid Technology Hub - Centre of Excellence, Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
免疫疗法显示出有希望的结果,但由于癌症的免疫抑制瘤微环境 (TME),往往会失败. 准TME新陈代谢可能会增强抗瘤免疫反应并提高癌症治疗效率.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 癌症生物学 癌症生物学
背景情况:
- 免疫系统对病原体,损伤和癌症进行防御.
- 免疫疗法,包括免疫检查点疗法 (ICT) 和使用CAR T细胞采用细胞移植 (ACT),旨在增强抗癌免疫力.
- 对ICT的高耐药率 (60-80%) 强调了需要了解癌症免疫抑制的必要性.
研究的目的:
- 探索瘤微环境 (TME) 的向潜力,以克服免疫疗法耐药性.
- 调查TME代谢重编程如何促进固体瘤中的免疫抑制.
- 讨论通过准TME代谢来规范瘤血管化和增强抗瘤免疫力的策略.
主要方法:
- 审查目前对固体瘤中免疫抑制性TME的理解.
- 分析TME内的代谢压力因素,包括营养竞争和酸化.
- 讨论针对TME代谢的潜在治疗策略.
主要成果:
- 固体瘤 (大约2个月) 90%的癌症) 产生一种免疫抑制的TME.
- 肌痛性脑膜炎的功能障碍包括血管化不良,输液受损和缺氧.
- 在TME中,代谢压力会激活免疫抑制途径.
结论:
- 针对TME代谢提供了一个有希望的策略,以提高免疫治疗的疗效.
- 调节TME新陈代谢可能会使瘤血管化正常化,并改善抗瘤免疫反应.
- 了解TME代谢重编程对于开发更有效的癌症疗法至关重要.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
09:42Assessing Tumor Microenvironment of Metastasis Doorway-Mediated Vascular Permeability Associated with Cancer Cell Dissemination using Intravital Imaging and Fixed Tissue Analysis
Published on: June 26, 2019
相关概念视频
The Tumor Microenvironment
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Tumor Immunotherapy
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...